HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Zacks Rank    Equity Research    Premium Home    My Account    Help    

Zacks #1 Rank
See how a purely mathematical analysis of earnings estimate revisions returns over 27% per year on average. Click Here to Learn More.
Quote:
Login Free Membership
Search:

 
Analyst Blog  

MASI’s Agreement with German Co.

August 21, 2009 | Comments: 0
Recommended this article (1)
MASI | HAE | BDX
Print    Share

Masimo Corporation
(MASI - Analyst Report) announced that it has signed a new worldwide technology licensing agreement with GS Elektromedizinische Gerate G. Stemple GmbH that will enable the latter to integrate Masimo’s Rainbow SET Pulse CO-Oximetry into its corpuls patient monitoring modules.

GS Elektromedizinische Gerate G. Stemple GmbH is a leading German company that develops and manufactures innovative medical equipment for Emergency Medical Services (EMS) and intensive care. The company is a market leader in providing innovative EMS solutions throughout Europe. The company’s corpuls patient monitoring modules and defibrillators are used in the first aid treatment of patients suffering from sudden cardiac arrest.

Masimo’s Rainbow SET Pulse CO-Oximetry allows for continuous monitoring of hemoglobin, carbon monoxide, methemoglobin, PVI for fluid responsiveness, perfusion index and measure-through motion pulse oximetry.

The integration of the Rainbow SET Pulse CO-Oximetry will enhance the efficiency of GS GmbH’s defibrillators and patient monitoring systems that help EMS professionals detect and treat life-threatening conditions at an earlier stage.

Though the financial terms of the agreement have not been disclosed, we believe that the deal will enhance Masimo’s international revenues. Masimo Corporation develops, manufactures and markets a family of non-invasive blood monitoring systems that consist of a monitor, circuit board and sensors. The systems are primarily used to monitor blood oxygen saturation levels and protect against hypoxemia and hyperoxemia.

Hypoxemia, low blood-oxygen levels, can result in brain damage and death. Hyperoxemia, high-blood oxygen levels, can result in permanent eye-damage and blindness.

Masimo is a market leader in the pulse oximetry monitoring equipment market industry. The company's closest competitors are Haemonetics Corporation (HAE - Analyst Report) and Becton, Dickinson and Company (BDX - Analyst Report). During fiscal 2008, the company gained five additional points of market share, taking the total to 43.5%.

Email

Print

Share

RSS

Rate Pos

Rate Neg

Comment
Read/Post Comments (0) | Recommended this article (1)
 Posting Comment...
There was a problem posting this this comment. Please try back later.
[CLICK TO CLOSE X]
Comments (Limit 1000 Characters - Used: 0)
Display Name: Email Address:  
 Loading Comments...
Be the first to comment on this article!
Best Stocks. Best Insight. Join Now...it's FREE!
Over 550,000 investors look forward to the timely insights in our email newsletter; Zacks Profit from the Pros. In each daily issue you will find:
  • Free  Four Zacks #1 Rank "Strong Buy" Stocks
  • Free  Timely Market Commentary
  • Free  Wealth Management Tips
  • Free  Profitable Strategy Screens
  • Free  Bull and Bear Stocks of the Day
Zacks FREE Registration

More Zacks Resources

Market Summary Nov 26, 2009 04:54 am ET
DJIA 10464.4  30.69 0.29%
NASD 2176.05  6.87 0.32%
S&P 500 1110.63  4.98 0.45%
Sponsored Links